Discovery of antibodies.
- 21 November 1992
- Vol. 305 (6864) , 1269-1272
- https://doi.org/10.1136/bmj.305.6864.1269
Abstract
Passive immunisation has been used in clinical practice since the end of last century, mainly for prophylaxis. Success of early treatments was marred by anaphylactic reactions and serum sickness because antibodies or antitoxins were not raised in humans. Recombination of gene segments during antibody synthesis means that specific antibodies for numerous antigens can be produced from a limited gene pool. Killer lymphocytes, phagocytes, and complement then bind to the constant region of the antibody facilitating elimination of the pathogen. Development of a method of obtaining large quantities of antibodies against a specific antigen (monoclonal antibodies) offers the possibility of initiating host defence mechanisms against any unwanted antigen, though some problems still remain in preventing the body from attacking the monoclonal antibody.Keywords
This publication has 16 references indexed in Scilit:
- Conformations of immunoglobulin hypervariable regionsNature, 1989
- Mutation Drift and Repertoire Shift in the Maturation of the Immune ResponseImmunological Reviews, 1987
- Somatic generation of antibody diversityNature, 1983
- Continuous production of monoclonal rheumatoid factor by EBV-transformed lymphocytesNature, 1980
- Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: Differentiation antigens of rat lymphocytesCell, 1977
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975
- Emil Behring and Paul Ehrlich: Their Contributions to ScienceNature, 1955
- Paul EhrlichBMJ, 1954
- Emil von BehringBMJ, 1954
- CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XI. THE USE OF CONCENTRATED NORMAL HUMAN SERUM GAMMA GLOBULIN (HUMAN IMMUNE SERUM GLOBULIN) IN THE PROPHYLAXIS AND TREATMENT OF MEASLES 12Journal of Clinical Investigation, 1944